Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website https://www.cardiologyres.org

Original Article

Volume 9, Number 2, April 2018, pages 107-110

Eptifibatide Bolus Dose During Elective Percutaneous Coronary Intervention

Tables

Table 1. Baseline and Angiographic Findings Between Bolus and Bolus + Infusion Group
 
Bolus groupBolus + infusion groupP value
Age (years)59.24 ± 10.9155.89 ± 12.350.47
Male gender32 (78%)14 (73.7%)0.47
Body mass index (kg/m2)28.76 ± 4.4027.32 ± 4.390.29
Smoking12 (29.3%)7 (36.8%)0.18
Hypertension19 (46.3%)4 (21.1%)0.06
Diabetes11 (26.8%)3 (15.8%)0.34
Hemoglobin (mg/dL)14.03 ± 1.9614.00 ± 2.580.96
Low platelet01 (5.3%)0.31
Involved vessels0.30
  Single8 (19.5%)6 (31.6%)
  2 - 333 (80.5%)13 (68.4%)
Involved coronary0.39
  LAD25 (61%)12 (63.1%)
  RCA9 (22%)6 (31.5%)
  LCX7 (17%)1 (5.2%)

 

Table 2. In-Hospital and During Follow-Up MACE Between Bolus and Bolus + Infusion Group
 
Bolus groupBolus + infusion groupP value
Total MACE
  In-hospital8 (19.5%)6 (31.6%)0.30
  Follow-up6 (15.4%)3 (17.6%)0.83
Bleeding
  In-hospital6 (14.6%)4 (21.1%)0.39
  Follow-up1 (2.4%)1 (5.3%)0.53
Re-MI
  In-hospital01 (5.3%)-
  Follow-up00-
Revascularization
  In-hospital1 (2.4%)0-
  Follow-up1 (2.4%)2 (10.5%)0.23
Mortality
  In-hospital2 (4.9%)3 (15.8%)0.31
  Follow-up4 (10.3%)00.31